Quest Diagnostics Incorporated (DGX) — Fair Value Analysis

Base-case fair value (P50): $219.14 · Current price: $215.72 · Verdict: Fairly Valued

The Verdict on DGX

Quest Diagnostics (DGX) appears Fairly Valued based on our Monte Carlo simulations. Currently trading at $215.72, DGX's median fair value (P50) is projected at $219.14. This indicates a modest +1.6% potential upside from its current level, aligning with our 'Fairly Valued' assessment. The small divergence between the market price and our P50 fair value suggests that the stock is largely trading near its intrinsic worth. The stock’s average quality tier, reflecting its operational and financial health within the Healthcare sector, supports this balanced outlook, indicating that it neither presents significant undervaluation nor appears overtly overstretched.

How DGX stacks up against Healthcare

Within the Healthcare sector, Quest Diagnostics (DGX) holds an average quality tier. This assessment, derived from its operational and financial health, suggests DGX is neither an extreme outlier nor a top-tier performer when compared to its industry peers. The +1.6% upside from the current $215.72 to the $219.14 median fair value is consistent with a company in this quality bracket, where significant mispricings are less common. While some Healthcare stocks might present more extreme valuation gaps, DGX's current positioning aligns closely with its simulated fair value, indicating a market price that largely reflects its intrinsic worth given its average quality.

What this means for investors

For investors, the 'Fairly Valued' verdict for Quest Diagnostics (DGX) at $215.72, with a median fair value of $219.14 and +1.6% upside, implies that immediate, substantial arbitrage opportunities are limited. The Monte Carlo simulations suggest a relatively efficient pricing of the stock, reflecting its average operational and financial health within the Healthcare sector. While there's potential for modest upside scenarios, downside scenarios also exist, underscoring the importance of understanding the full probabilistic range. FairCurve's analysis, with its average quality tier rating for DGX, highlights that investors should expect returns commensurate with its industry standing rather than outsized gains driven by deep undervaluation. Sign up for a free FairCurve account to see the full bear/bull distribution and track DGX's fair value as new fundamentals are released.